Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25522 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL15270535 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL29691 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL1482019 | 0.89 | — | — | |
| SCHEMBL3457952 | 0.89 | — | — | |
| Phosphoric Acid SCHEMBL1702589 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL6757235 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Ammonia Solution, Strong SCHEMBL4757962 | 0.89 | — | — | |
| Phosphoric Acid SCHEMBL8672233 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL2696248 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378531-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | Thomas Jefferson University (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024077130-A1 | METHODS AND COMPOSITIONS FOR TREATING BLADDER CANCER | THOMAS JEFFERSON UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240100078-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | UNIV JEFFERSON (US) | 2024-03-28 | — | — | US | disclosed |
| EP-3592841-B1 | COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | UNIV JEFFERSON (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023209220-A1 | TARGETING MICRO RNA FOR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2023-11-02 | — | — | WO | disclosed |
| EP-4269586-A1 | TARGETING MICRO RNA FOR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-11801259-B2 | Methods and compositions for treating cancers using antisense | THOMAS JEFFERSON UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220195440-A1 | METHODS FOR TREATING CANCERS USING ANTISENSE | UNIV JEFFERSON (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220133800-A1 | TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING | TGM LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3946287-A1 | METHODS FOR TREATING CANCERS USING ANTISENSE | Thomas Jefferson University (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-2440566-A1 | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS | Miragen Therapeutics (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144485-A1 | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS | MIRAGEN THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-0734391-B1 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1201676-A2 | PNA-DNA-PNA chimeric macromolecules | ISIS PHARMACEUTICALS, INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6277603-B1 | PEPTIDE NUCLEIC ACID (PNA); THE DNA PORTION IS COMPOSED OF SUBUNITS OF AT LEAST ONE 2'-DEOXYNUCLEOTIDES; INCREASED NUCLEASE RESISTANCE; ACTIVATE RNASE H ENZYME, USE FOR IN VITRO MODIFICATION OF RNA | ISIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-0734391-A4 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS INC (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5700922-A | INCREASED NUCLEASE RESISTANCE, INCREASED BINDING AFFINITY TO COMPLEMENTARY STRANDS; MEDICAL DIAGNOSIS, THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0734391-A1 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996024558-A1 | METHOD AND APPARATUS FOR THERMAL DECOMPOSITION AND SEPARATION OF COMPONENTS WITHIN AN AQUEOUS STREAM | HPR CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| WO-1995014706-A1 | PNA-DNA-PNA CHIMERIC MACROMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |